Global Newsroom | CSL
WEBCSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU. Jun 11, 2024 - CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in …
News Releases - CSL
WEBApr 17, 2024 · Swissmedic Authorises CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B. CSL's HEMGENIX® is a one-time, single-dose treatment for male adults with severe/moderately severe hemophilia B BERN, Switzerland, Jan. 15, 2024 /PRNewswire/ -- Global biotechnology leader CSL... Dec 21, 2023.
News Releases - CSL
WEBMay 30, 2024 · CSL enters into Strategic Option and License Agreement with Translational Sciences. Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced …
News Releases | CSL
WEBNov 2, 2022 · MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 / PRNewswire / -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health.
News Releases - CSL
WEBFeb 12, 2024 · CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.
News Releases - CSL
WEBKING OF PRUSSIA, Pa., Feb. 26, 2023 / PRNewswire / -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL's investigational first-in-class monoclonal antibody being developed as a …
CSL Announces Closing of Global Collaboration and Licensing …
WEBDec 12, 2022 · CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...
News Releases - CSL
WEBJun 24, 2022 · First doses were rolled out in March 2021, with over 40 million doses released as of June 2022. In 2020, CSL worked with the University of Queensland in the early stages of its UQ-CSL v451 COVID-19 vaccine candidate. A Phase I clinical trial showed that the vaccine elicited a robust response towards the virus and had a …
CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY
WEBMELBOURNE, Australia, Aug. 10, 2022 / PRNewswire / -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand. "As a purpose-driven organization, CSL has delivered biotechnology excellence for over a century," said Paul Perreault, Chief Executive Officer and Managing Director of CSL.
News Releases | CSL
WEB19 Oct 2022. MELBOURNE, AUSTRALIA: Global biotechnology leader CSL’s new global corporate headquarters has been awarded a five-star rating from the Green Building Council of Australia. In August this year, CSL announced new carbon targets as part of its broader sustainability strategy and a commitment to a healthier world.
Skip to content